Evaluation of interim modifications for extended dosing intervals of durvalumab for locally advanced unresectable stage III non-small cell lung cancer during the COVID-19pandemic
Xiaochen Tai, Caroline E. Muñoz, Jessica Arias, Andrew G. Robinson, M. Sara Kuruvilla, Stephanie Brulé, Munaza Chaudhry, Scott Gavura, Steven Habbous, Nibene Somé, Kelvin K. W. Chan